Targeting functionalized nanoparticles to activated endothelial cells under high wall shear stress.
drug delivery
endothelium
inflammation
microfluidics
shear stress
vascular‐targeted carriers (VTCs)
Journal
Bioengineering & translational medicine
ISSN: 2380-6761
Titre abrégé: Bioeng Transl Med
Pays: United States
ID NLM: 101689146
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
24
09
2019
revised:
12
11
2019
accepted:
03
12
2019
entrez:
23
5
2020
pubmed:
23
5
2020
medline:
23
5
2020
Statut:
epublish
Résumé
Local inflammation of the endothelium is associated with a plethora of cardiovascular diseases. Vascular-targeted carriers (VTCs) have been advocated to provide focal effective therapeutics to these disease sites. Here, we examine the design of functionalized nanoparticles (NPs) as VTCs that can specifically localize at an inflamed vessel wall under pathological levels of high shear stress, associated for example with clinical (or in vivo) conditions of vascular narrowing and arteriogenesis. To test this, carboxylated fluorescent 200 nm polystyrene particles were functionalized with ligands to activated endothelium, that is, an E-selectin binding peptide (Esbp), an anti ICAM-1 antibody, or using a combination of both. The functionalized NPs were investigated in vitro using microfluidic models lined with inflamed (TNF-α stimulated) and control endothelial cells (EC). Specifically, their adhesion was monitored under different relevant wall shear stresses (i.e., 40-300 dyne/cm
Identifiants
pubmed: 32440559
doi: 10.1002/btm2.10151
pii: BTM210151
pmc: PMC7237145
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e10151Informations de copyright
© 2019 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals, Inc. on behalf of The American Institute of Chemical Engineers.
Déclaration de conflit d'intérêts
The authors declare no potential conflict of interest.
Références
Expert Opin Drug Deliv. 2018 Jan;15(1):33-45
pubmed: 28388248
Exp Biol Med (Maywood). 2017 Apr;242(8):799-812
pubmed: 28195515
Biophys J. 2000 Oct;79(4):1891-902
pubmed: 11023895
J Control Release. 2009 Dec 3;140(2):100-7
pubmed: 19666063
J Clin Pharmacol. 2015 Mar;55 Suppl 3:S4-20
pubmed: 25707963
Biophys J. 2003 Oct;85(4):2720-31
pubmed: 14507735
Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1143-51
pubmed: 12676799
J Clin Invest. 1994 Aug;94(2):885-91
pubmed: 7518844
Biomaterials. 2005 Dec;26(34):7136-44
pubmed: 15953632
Bioeng Transl Med. 2016 Mar;1(1):103-115
pubmed: 28066821
J Thromb Haemost. 2017 May;15(5):972-982
pubmed: 28267256
Physiol Rev. 2018 Jan 1;98(1):3-58
pubmed: 29167330
Nat Nanotechnol. 2014 Mar;9(3):204-10
pubmed: 24561355
IUBMB Life. 2011 Aug;63(8):586-95
pubmed: 21766415
Biomaterials. 2010 Feb;31(5):900-7
pubmed: 19879646
ACS Nano. 2013 Mar 26;7(3):2461-9
pubmed: 23383962
Curr Opin Nephrol Hypertens. 2003 Mar;12(2):181-7
pubmed: 12589179
ACS Cent Sci. 2016 Jul 27;2(7):434-7
pubmed: 27504489
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7562-7
pubmed: 9636189
Trends Mol Med. 2003 Jun;9(6):263-8
pubmed: 12829015
JAMA. 1999 Dec 1;282(21):2035-42
pubmed: 10591386
Biomaterials. 2009 Nov;30(32):6460-8
pubmed: 19716600
Arterioscler Thromb Vasc Biol. 1995 Jan;15(1):2-10
pubmed: 7538423
Biomaterials. 2010 Feb;31(6):1392-402
pubmed: 19954839
J Biomech. 2017 Jan 4;50:217-221
pubmed: 27863741
Pharmacol Rep. 2009 Jan-Feb;61(1):22-32
pubmed: 19307690
Trends Biotechnol. 1994 Sep;12(9):339-45
pubmed: 7521172
Biomed Microdevices. 2010 Dec;12(6):1001-8
pubmed: 20665114
Atherosclerosis. 2011 Aug;217(2):364-70
pubmed: 21601207
Mol Ther. 2008 Aug;16(8):1450-8
pubmed: 18560419
Ann Biomed Eng. 2013 Jul;41(7):1411-27
pubmed: 23229281
Science. 2012 Aug 10;337(6095):738-42
pubmed: 22767894